Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table S3 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
  1. Home
  2. Publications
  3. Supplementary Table S3 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer

Supplementary Table S3 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer

Authors:
  • YQYunkai Qie
    Yunkai Qie
  • SHShiwang Huang
    Shiwang Huang
  • CSChong Shen
    Chong Shen
  • ZWZhouliang Wu
    Zhouliang Wu
  • LDLa Da
    La Da
  • KJKaipeng Jia
    Kaipeng Jia
  • ZZZhe Zhang
    Zhe Zhang
  • GZGangjian Zhao
    Gangjian Zhao
  • LWLili Wang
    Lili Wang
  • GXGuoping Xu
    Guoping Xu
  • YZYang Zhao
    Yang Zhao
  • RLRui Liang
    Rui Liang

Open Access
Publisher website
Google Scholar
  • 3 March 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.28523304
Abstract
Supplementary Table S3. Immune-mediated adverse events.
Keywords
  • CLINICAL TRIAL RESULTS
  • PHASE II CLINICAL TRIALS
  • GENITOURINARY CANCERS
  • BLADDER CANCER
  • IMMUNOTHERAPY
  • CHECKPOINT BLOCKADE
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.